The PAROPE (Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely) study is an observational longitudinal research project designed to characterize and quantify eye movement abnormalities across different Parkinsonian syndromes using advanced oculometric techniques. This study addresses a critical need in movement disorder neurology: the development of objective, quantitative biomarkers that can assist in differentiating between Parkinson's disease (PD) and atypical parkinsonian disorders such as Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS).
Eye movement abnormalities are among the most distinctive features of atypical parkinsonism, yet their clinical assessment remains largely qualitative and dependent on examiner expertise. The PAROPE study aims to change this paradigm by systematically applying oculometric measurement to create objective diagnostic and progression markers that could eventually be used in clinical practice and clinical trials 1.
- NCT Number: NCT06597071
- Title: Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
- Status: Enrolling by Invitation
- Study Type: Observational
- Design: Longitudinal cohort study
- Cohorts: 4 groups of Parkinsonian syndromes
- Sponsor: Major academic medical center with movement disorders program
- Enrollment: Target 200 participants
- Follow-up: 24 months
¶ Background and Rationale
Oculomotor dysfunction is a hallmark of many neurodegenerative diseases, but it is particularly prominent and distinctive in atypical parkinsonian disorders:
Progressive Supranuclear Palsy: Vertical supranuclear gaze palsy is one of the defining features of PSP, affecting over 90% of patients during the disease course. The inability to voluntarily move eyes vertically (especially downward) is a core diagnostic criterion and often appears early in the disease.
Multiple System Atrophy: Oculomotor abnormalities in MSA include saccadic pursuit, gaze-evoked nystagmus, and impaired convergence. These reflect the involvement of brainstem oculomotor nuclei and cerebellar pathways.
Cortical Basal Syndrome: Eye movement disturbances in CBS reflect cortical involvement, with slowed saccades, apraxia of eyelid opening, and reduced blink rate.
Parkinson's Disease: While less pronounced than in atypical disorders, PD patients show reduced saccadic velocity, hypometric saccades, and delayed anti-saccade performance.
The clinical assessment of eye movements has several limitations:
- Subjectivity: Bedside oculomotor examination depends heavily on examiner skill and experience
- Quantification: Current clinical scales lack quantitative precision
- Sensitivity: Subtle abnormalities may be missed in early disease stages
- Reproducibility: Inter-rater reliability is limited
- Disease Monitoring: Clinical rating scales are insensitive to small changes over time
Oculometry offers a solution to these challenges:
- Precision: Eye-tracking technology can measure movements with millisecond temporal resolution and sub-degree spatial resolution
- Quantification: Every aspect of eye movement can be expressed as a numerical value
- Standardization: Automated testing removes inter-examiner variability
- Sensitivity: Subtle abnormalities detectable before clinical symptoms
- Longitudinal Tracking: Objective measures of disease progression
-
Characterize Oculometric Profiles: Define specific patterns of eye movement abnormalities for each Parkinsonian syndrome:
- Saccade parameters (velocity, latency, accuracy, peak acceleration)
- Pursuit characteristics (gain, catch-up saccades)
- Anti-saccade performance (error rate, correction rate)
- Fixation stability (saccadic intrusions, drift)
-
Diagnostic Differentiation: Establish which oculometric measures best differentiate:
- PSP from PD
- MSA from PD
- CBS from PD
- PSP from CBS
- PSP from MSA
-
Longitudinal Progression: Characterize how oculometric measures change over time:
- Rate of decline in different disorders
- Correlation with clinical progression
- Predictive value for disease trajectory
-
Clinical Correlation: Establish relationships between oculometric measures and:
- Standard clinical rating scales (MDS-UPDRS, PSP Rating Scale, UMSARS)
- Disease duration
- Cognitive function
- Quality of life measures
- Develop diagnostic algorithms using machine learning
- Validate oculometric endpoints for clinical trials
- Establish reference values for clinical interpretation
- Compare oculometric vs. other biomarker modalities
The PAROPE study employs video-oculography (VOG) systems that use infrared cameras to track pupil position:
High-Speed Cameras: Sampling rates of 250-500 Hz allow precise measurement of rapid saccades
Spatial Resolution: Sub-pixel algorithms achieve accuracy of 0.1-0.5 degrees
Calibration: Standardized calibration procedures ensure accurate gaze position measurement
Participants undergo a comprehensive oculometric assessment:
Saccade Tasks:
- Reflexive Saccades: Look at suddenly appearing targets
- Memory-Guided Saccades: Look to remembered locations
- Anti-Saccades: Look away from visual targets (measures executive control)
- Predictive Saccades: Track predictable target motion
Pursuit Tasks:
- Smooth Pursuit: Track smoothly moving targets at various velocities
- Cue-Accelerated Smooth Pursuit: Anticipatory pursuit following cues
- Ramp and Step-Ramp Paradigms: Distinguish predictive vs. reactive pursuit
Fixation Tasks:
- Center Fixation: Maintain gaze on central target
- Peripheral Fixation: Hold gaze on eccentric targets
- Blank Trials: Detect spontaneous saccadic intrusions
Other Measures:
- Blink Rate: Automated measurement during viewing
- Pupil Size: Light and cognitive pupil responses
- Convergence: Near-far accommodation measures
- Classic PD diagnosis
- No atypical features
- Disease duration 2-10 years
- On dopaminergic therapy
- Clinical diagnosis of PSP (any variant)
- Richardson's syndrome or variants
- May include early-stage patients
- Either parkinsonian or cerebellar variant
- Autonomic dysfunction present
- Appropriate neuroimaging findings
- Asymmetric presentation
- Cortical features present
- Appropriate clinical criteria
- Age-matched comparison
- No neurological disease
- Normal eye examination
¶ Standardized Rating Scales
For All Participants:
- Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
- Montreal Cognitive Assessment (MoCA)
- Beck Depression Inventory (BDI)
For PSP Patients:
- PSP Rating Scale (PSPRS)
- Frontal Assessment Battery (FAB)
For MSA Patients:
- Unified Multiple System Atrophy Rating Scale (UMSARS)
For CBS Patients:
- Corticobasal Syndrome Rating Scale (CBS-RS)
- Detailed oculomotor examination (all conventional tests)
- General neurological assessment
- Motor examination
- Assessment of autonomic function
- Brain MRI (for diagnostic confirmation)
- DaTscan (dopamine transporter imaging) in selected cases
- CSF sampling (where clinically indicated)
Modern VOG systems have several key components:
Camera Systems:
- Infrared cameras for pupil tracking
- Sampling rates: 250-500 Hz for accurate saccade capture
- Spatial resolution: 0.1-0.5 degrees
Analysis Software:
- Automated artifact rejection
- Velocity calculation algorithms
- Calibration routines
Search Coil Oculography:
- High accuracy (<0.01 degrees)
- Contact lens with embedded coil
- Limited to horizontal/vertical
- More invasive than VOG
Electro-oculography (EOG):
- Electrodes around eyes
- Lower cost and complexity
- Less accurate than VOG
- Useful for screening
¶ Validation and Standardization
The PAROPE study addresses standardization needs:
- Inter-device comparison
- Normal value establishment
- Test-retest reliability assessment
- Cross-site calibration
¶ Regulatory and Clinical Implementation
Oculometric endpoints are undergoing regulatory qualification:
Qualification Status:
- ALS oculometric endpoints qualified
- PD endpoints under review
- PSP endpoints in development
Requirements for Qualification:
- Analytical validation
- Clinical validation
- Demonstration of clinical relevance
Several challenges must be addressed:
Technology Access:
- Cost of eye-tracking equipment
- Need for specialized expertise
- Infrastructure requirements
Standardization:
- Lack of universal protocols
- Variability in analysis methods
- Reference values needed
Potential clinical applications:
Diagnostic Aid:
- Early disease detection
- Differential diagnosis support
- Disease subtype classification
Monitoring:
- Track progression
- Assess treatment response
- Identify complications
Research:
- Clinical trial endpoints
- Biomarker development
- Mechanistic studies
The study will apply machine learning algorithms to develop diagnostic classifiers:
Feature Engineering:
- Extract >50 parameters from each oculometric test
- Include temporal dynamics (velocity profiles, acceleration)
- Combine across all test types
Classification Methods:
- Support Vector Machines (SVM)
- Random Forest classifiers
- Neural network approaches
- Ensemble methods
Validation:
- Cross-validation within cohort
- Independent validation on held-out test set
- Comparison with clinical diagnosis
For progression tracking:
- Mixed-effects models for change over time
- Growth curve modeling
- Survival analysis for time-to-milestone
- Predictive modeling for individual trajectories
¶ Significance and Implications
Oculometric biomarkers could transform clinical practice:
-
Earlier Diagnosis: Quantitative measures may detect abnormalities before clinical diagnosis
-
Differential Diagnosis: Specific patterns could assist in distinguishing between disorders
-
Disease Staging: Oculometric measures could indicate disease severity and stage
-
Progression Prediction: Baseline measures might predict rate of progression
For therapeutic development:
-
Patient Selection: Oculometric measures could enrich trials for specific populations
-
Outcome Measures: Sensitive endpoints for demonstrating treatment effects
-
Target Engagement: Oculometric changes could indicate biological effect
-
Stratification: Baseline profiles could stratify patients for personalized treatment
The study will advance understanding of:
-
Neuroanatomy: Which brain regions contribute to specific oculomotor abnormalities
-
Pathophysiology: How different proteinopathies affect oculomotor circuits
-
Biomarker Development: Comparative value of oculometric vs. other biomarkers
-
Disease Mechanisms: Insights into how different disorders affect eye movement control
Deep Learning Analysis: New approaches applying convolutional neural networks to eye-tracking data have improved diagnostic accuracy to >90% in some comparisons 2.
Remote Monitoring: Web-based eye-tracking using standard webcams now enables at-home monitoring, reducing clinic visit burden 3.
Multi-Modal Integration: Combining oculometric data with speech analysis, gait assessment, and other digital biomarkers improves diagnostic discrimination 4.
FDA Qualification: The first oculometric endpoints have been qualified by FDA for clinical trials, enabling use as regulatory endpoints 5.
Portable Systems: New wireless eye-tracking headsets enable testing outside specialized laboratories
Virtual Reality: VR-based oculomotor testing provides standardized environments and immersive task designs
AI Integration: Automated analysis pipelines reduce processing time from hours to minutes
The brainstem contains several key nuclei controlling eye movements:
Cranial Nerve Nuclei:
- Oculomotor nucleus (CN III): Controls most extraocular muscles, levator palpebrae
- Trochlear nucleus (CN IV): Controls superior oblique muscle
- Abducens nucleus (CN VI): Controls lateral rectus muscle
Paramedian Pontine Reticular Formation (PPRF):
- Horizontal saccade generation
- Integrated with burst neurons for rapid eye movements
- Affected in PSP leading to saccadic impairments
Superior Colliculus:
- Visual-motor integration
- Saccade target selection
- Deep layers receive multimodal sensory input
The basal ganglia modulate oculomotor behavior through indirect pathways:
Direct Pathway (facilitates movement):
- Facilitation of intended saccades
- Suppression of competing saccades
Indirect Pathway (inhibits movement)**:
- Suppression of unwanted saccades
- Gating of reflexive movements
Hyperdirect Pathway:
- Rapid inhibition of saccades
- Involved in stop-signal tasks
In Parkinson's disease and atypical parkinsonism, basal ganglia dysfunction leads to:
- Reduced saccadic velocity
- Impaired anti-saccade performance
- Difficulty with predictive saccades
The cerebellumFine-tunes saccadic movements:
Fastigial Nucleus:
- Controls saccadic accuracy
- Corrects hypermetric saccades
- Lesions cause dysmetria
Purkinje Cells:
- Modulate movement timing
- Coordinate saccadic sequences
- Support adaptive learning
In MSA, cerebellar involvement leads to:
- Gaze-evoked nystagmus
- Impaired pursuit gain
- Oculomotor ataxia